She joins us from Johnson & Johnson, where as Vice President of External Innovation and Global Leader for Regulatory Science, she led 900 employees across J&J’s medical device companies, specializing in using cutting-edge tools and innovative methods to bring new breakthroughs to patients.
And she knows Washington, having held a leadership role at the U.S. Food and Drug Administration’s Center for Devices and Radiological Health. She also served on the Obama administration’s Science Transition Team and led health and science policy on Capitol Hill for Sen. Joe Lieberman.
And she's ready to roll up her sleeves and embrace the key role biotechnology plays in protecting our planet's resources, driving a strong economy by driving a strong bioeconomy, and improving people's lives.
Get to know Dr. Michelle, in one minute:
So, what’s next for BIO? “There’s a time for us to tell a new story—to turn the page and talk about what science has been able to do to make patients feel better, make our country safer, make our country more prosperous,” she says. “Going forward, it’s going to be more important than ever to tell that story and tell it loudly.”
Last but not least, we want to thank Jim Greenwood, again, for his 15 years of strong leadership. Since he took the helm in 2005, BIO tripled in size and has had many accomplishments—perhaps most notably, the unprecedented Coronavirus Collaboration Initiative to work together on COVID-19 vaccines and treatments. Jim will be sticking around for a bit, assisting Michelle in a strategic advisory role—and you’ll be able to hear from him again during BIO Digital next week.
Visit www.bio.org/DrMichelle to learn more about Dr. McMurry-Heath and submit any suggestions for BIO’s new chapter.
Read more about her in this profile in STAT.
More News:
Biopharma Dive: Lilly wins first-ever FDA approval for drug that can spot Alzheimer's 'tau tangles'
“Its approval is based on two clinical trials which found a high likelihood that 'evaluators' could correctly identify tau pathology from a Tauvid scan. Before, the only way to get an in-depth look at these tangles was through an autopsy.”
S&P Global: Renewable energy consumption topped coal in 2019 for the first time since 1885
“U.S. renewable energy consumption in 2019 surpassed coal energy consumption for the first time in 130 years as coal used for electricity continues to decline while more renewables are joining the grid as part of an energy transition to cleaner power sources, according to the U.S. Energy Information Administration's Monthly Energy Review.”
The Wall Street Journal: Eli Lilly begins testing COVID-19 drug derived from blood of survivor
“The drugmaker also plans eventually to test whether the antibody-based drug could prevent disease in people at risk of infection, an approach that could serve as a bridge toward curbing the pandemic until a successful vaccine is developed.”
